Intelligene, Inc.
Biotechnology company focused on developing siRNA-based therapeutics and RNA delivery systems. The company develops RNA interference (RNAi) drug candidates for infectious diseases (notably COVID-19 and influenza), and operates a GMP pilot plant for formulation, scale-up and manufacturing of lipid nanoparticle (LNP) and engineered exosome delivery systems. It pursues collaborations for clinical development and commercialization.
Industries
N/A
Nr. of Employees
small (1-50)
Intelligene, Inc.
14F.-6, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei, Taiwan
Products
IG-001
siRNA-based therapeutic candidate intended to treat SARS-CoV-2 (COVID-19). Phase I clinical trials were planned to begin in the year referenced in public announcements; development is supported via international collaboration.
IG-002
siRNA-based therapeutic candidate aimed at broad-spectrum influenza treatment; development stage indicated as preclinical or discovery in public materials.
IG-001
siRNA-based therapeutic candidate intended to treat SARS-CoV-2 (COVID-19). Phase I clinical trials were planned to begin in the year referenced in public announcements; development is supported via international collaboration.
IG-002
siRNA-based therapeutic candidate aimed at broad-spectrum influenza treatment; development stage indicated as preclinical or discovery in public materials.
Services
Pilot-scale manufacturing, process development and scale-up services for RNA therapeutics and delivery carriers operating in a GMP-compliant facility.
Development and optimization of lipid nanoparticle and engineered exosome formulations to protect and deliver RNA payloads to target tissues.
Support for preclinical development and early-phase clinical trial planning, including regulatory and manufacturing strategy through collaborative programs.
Pilot-scale manufacturing, process development and scale-up services for RNA therapeutics and delivery carriers operating in a GMP-compliant facility.
Development and optimization of lipid nanoparticle and engineered exosome formulations to protect and deliver RNA payloads to target tissues.
Support for preclinical development and early-phase clinical trial planning, including regulatory and manufacturing strategy through collaborative programs.
Expertise Areas
- siRNA therapeutics development
- RNA drug delivery (LNP and exosome carriers)
- Pilot-scale GMP manufacturing and process development
- Formulation and purification for nanoparticle and vesicle carriers
Key Technologies
- siRNA / RNA interference (RNAi)
- Lipid nanoparticles (LNPs)
- Engineered exosomes / extracellular vesicles (EVs)
- Pilot-scale GMP manufacturing
News & Updates
Announcement of a partnership under the BRIDGE program to support development of IG-001 with funding and expert support, and plan to conduct Phase I trials in Australia.
Public announcements regarding company registration and plans for listing on local stock market platforms; investor materials and financial reporting are provided on investor pages.
Announcement of a partnership under the BRIDGE program to support development of IG-001 with funding and expert support, and plan to conduct Phase I trials in Australia.
Public announcements regarding company registration and plans for listing on local stock market platforms; investor materials and financial reporting are provided on investor pages.